The parasite's survival trick is also its weakness
For nearly two decades, a pair of Israeli chemists pursued the inner architecture of one of humanity's oldest killers, driven by personal memory and scientific curiosity in equal measure. At the Weizmann Institute of Science, Leslie Leiserowitz and Michael Elbaum led an international team of 17 researchers to produce the first complete atomic map of hemozoin — the dark crystals a malaria parasite builds to neutralize its own toxic waste and survive inside human blood. The discovery matters because most antimalarial drugs work by disrupting this very crystallization process, and understanding its precise geometry may finally allow scientists to outpace the drug-resistant strains that still claim more than half a million lives each year, most of them children.
- Malaria kills over 500,000 people annually — predominantly young children — and drug-resistant strains are eroding the arsenal of treatments that once brought the disease under partial control.
- The parasite's survival hinges on a chemical sleight of hand: it converts toxic heme, a byproduct of digesting hemoglobin, into inert hemozoin crystals — and most existing drugs attempt to jam that process without fully understanding its structure.
- A 17-scientist relay across five countries, using cryo-electron tomography, synchrotron imaging, and electron crystallography, has now mapped those crystals atom by atom — revealing that the parasite's real crystals differ in critical ways from the synthetic models researchers had long relied upon.
- The structural map exposed why hemozoin grows into its distinctive trapezoid shape: four different molecular building blocks, two of them mirror-image pairs, create an atomically disordered surface — the very surface where drugs must bind to stop crystal growth.
- With the fastest-growing and most drug-vulnerable crystal surfaces now identified, researchers have a concrete roadmap for engineering compounds that can block hemozoin formation and kill even resistant parasites.
Leslie Leiserowitz grew up in South Africa watching his father return from timber expeditions across the continent with the side effects of quinine still in his system. Decades later, as a crystallographer at Israel's Weizmann Institute of Science, he recognized that the malaria parasite itself was a crystal-maker — and that studying those crystals might be the work of a lifetime. Together with chemistry professor Michael Elbaum, he set out to map them.
The parasite faces a lethal chemical problem of its own making. Digesting hemoglobin releases heme, an iron-containing molecule so reactive it would destroy the organism. Its solution, honed over millions of years of evolution, is to pack that heme into dark, inert crystals called hemozoin. This is also its vulnerability: most antimalarial drugs work by interfering with that crystallization. Knowing the precise atomic structure of the crystals could make those drugs far more effective.
The investigation became a global relay. Leiserowitz and Elbaum began with cryo-electron tomography at Weizmann, then sent samples to Oxford and Britain's Diamond Light Source synchrotron, where a newly installed electron crystallography method produced images of unprecedented resolution. One discovery led to another collaboration, and the team eventually grew to 17 researchers across five countries.
The result was a three-dimensional atomic map that answered a long-standing puzzle: why do hemozoin crystals grow into trapezoid shapes, with one clean edge and one ragged end? The answer lies in the heme molecule's asymmetry. Because its front and back faces are chemically different, heme can pair in four distinct ways — two symmetric, two chiral, like left and right hands. When these building blocks grow together, they produce an atomically disordered surface, including that telltale jagged edge. Elbaum describes the drug mechanism with a factory analogy: if the drivers who move finished cars off the assembly line stop working, vehicles pile up, the line jams, and production halts. That is what happens when a drug prevents heme from binding to the crystal — it accumulates, clogs the cell membrane, and the parasite dies.
Critically, the study found that the crystals the parasite actually builds differ in subtle but important ways from the synthetic versions used in most prior research — a distinction that had quietly undermined drug design for years. The findings also identified which crystal surfaces grow fastest and which are most exposed to interference, offering a concrete roadmap for new compounds. Elbaum presented the results at a symposium marking Leiserowitz's 90th birthday, a milestone that coincided with publication of the study — a fitting close to nearly two decades of work on a single-celled organism's most ingenious trick for staying alive.
Leslie Leiserowitz first encountered malaria as a child in South Africa, watching his father return from timber expeditions across the continent with more than adventure stories—he brought back the side effects of quinine, the drug he took to prevent infection. Decades later, while studying crystal structures at Israel's Weizmann Institute of Science, Leiserowitz realized the parasite itself held the key to understanding something he'd spent his career investigating. The malaria organism, he learned, survives inside red blood cells by manufacturing crystals. He decided to study them.
That decision, made in collaboration with chemistry professor Michael Elbaum, has now yielded something remarkable: the first complete atomic map of the crystal structures that allow the malaria parasite to stay alive. The parasite faces a lethal problem. When it digests hemoglobin—the protein that carries oxygen in blood—the process releases heme, an iron-containing molecule so chemically reactive it would poison the organism. The parasite's solution is elegant and brutal: it neutralizes the heme by packing it into dark crystals called hemozoin, or malaria pigment. This survival trick, refined over millions of years of evolution, is also the parasite's vulnerability. Most antimalarial drugs work by interfering with crystal formation and growth. Understanding the precise atomic architecture of these crystals could unlock the design of far more effective medicines.
The research required an international relay of laboratories and the latest imaging technologies. Elbaum and Leiserowitz began with cryo-electron tomography at Weizmann, then sent their samples to colleagues at Oxford University and Britain's Diamond Light Source synchrotron, where a newly installed electron crystallography method produced unprecedented images. One discovery led to another collaboration, then another. The team eventually grew to 17 researchers across Israel, the United Kingdom, Austria, the Czech Republic, and the United States—a constellation of some of the world's most advanced labs working in concert to decode what a single-celled blood parasite had perfected.
The payoff was a three-dimensional structure mapped atom by atom. It solved a puzzle that had nagged at Leiserowitz for years: why did the hemozoin crystals grow into such peculiar trapezoid shapes, resembling kitchen knives with one sharp, clean edge and one jagged, irregular end? The answer lay in how heme molecules pair within the crystal lattice. Because the front and back faces of heme molecules are chemically different, they can pair in four distinct ways, creating four different building blocks. Two of these arrangements are symmetric; two are chiral—mirror images of each other, like left and right hands. When these different building blocks grow together in a single crystal, the result is an atomically disordered surface, including that telltale ragged edge. This level of structural clarity is essential for designing drugs that must bind to the crystal surface to stop its growth.
Elbaum explains the mechanism using a factory analogy: imagine producing 500 cars daily, but the drivers who remove them from the assembly line stop working. The vehicles pile up, jam the line, and nothing can move. That's what happens when a drug prevents heme molecules from advancing to bind with a crystal. They accumulate, clog the cell membranes, and the parasite dies. The new findings revealed something else critical: the natural crystals the parasite actually manufactures differ in subtle but essential ways from the synthetic crystals used in most previous research. This distinction matters enormously for drug design.
Malaria remains a catastrophic global health problem despite dramatic progress in the early 2000s. The disease kills more than half a million people annually, the vast majority of them young children. The crisis has been compounded by drug resistance—parasites have evolved immunity to many existing treatments, making the search for new weapons urgent. The research also identified which crystal surfaces grow fastest and which are most vulnerable to drug interference, providing a roadmap for developing compounds that can exploit these weaknesses. Elbaum presented the findings at a symposium celebrating Leiserowitz's 90th birthday, a milestone that coincided with publication of the study—a fitting capstone to nearly two decades of investigation into a parasite's most ingenious survival mechanism.
Citações Notáveis
We wondered how nature could produce something so ugly—these crystals looked as if they had been bitten on one side— Leslie Leiserowitz, Weizmann Institute
It was an opportunity we simply could not pass up— Michael Elbaum, on applying new imaging technologies to malaria research
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that they mapped the natural crystals rather than just studying the synthetic ones in the lab?
Because the parasite doesn't follow a recipe. The synthetic crystals are easier to make and study, but they're not what's actually happening inside a red blood cell. The real crystals have imperfections, asymmetries, weak points. A drug designed against a perfect laboratory crystal might miss those vulnerabilities entirely.
So the parasite's own survival trick is also its weakness?
Exactly. It has to make these crystals to survive the poison it creates. But the way it builds them—the way those heme molecules stack—leaves surfaces exposed. If you know which surfaces are most fragile, which ones grow fastest, you can design a drug that targets precisely those spots.
The article mentions this took 17 scientists from five countries. Why so many?
Each lab had mastered a different imaging technology. Weizmann had the cryo-electron tomography. Oxford had the new electron crystallography. You needed all of them working on the same samples to see the complete picture. It's like assembling a photograph from different wavelengths of light—no single lens captures everything.
Does this mean new drugs are coming soon?
Not immediately. What this gives you is the blueprint. Drug designers can now calculate how molecules will interact with these crystal surfaces, test thousands of compounds computationally before making a single one in the lab. It accelerates the process, but antimalarial development still takes years.
Why did Leiserowitz care about malaria in the first place?
His father came home from Africa with quinine side effects—rashes, tinnitus. That childhood memory stayed with him. Decades later, when he was deep in crystal research, he realized the parasite itself was a crystal problem. Sometimes the best science comes from connecting something you've always wondered about to something you've become expert in.